Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics.
To determine the frequency of human telomerase reverse transcriptase (hTERT) catalytic fraction expression and its association with clinical and demographic characteristics of the patient, as well as with the expression of CD34 and proliferating cell nuclear antigen (PCNA) indexes on adenohypophyseal hormone tissues. A transverse study was realized with 49 cases of hypophyseal adenoma with analysis type cases and controls. The different adenohypophyseal hormones [prolactin (PRL), growth hormone (GH), follicle stimulating hormone, luteinizing hormone, thyroid gland stimulant hormone, adrenocorticotropic hormone (ACTH)], the catalytic fraction of the telomerase hTERT, the PCNA index and the CD34 density were determined by means of immunohistochemical techniques. The clinical, demographic and histopathological characteristics of the patients with and without hTERT expression were compared by means of Pearson's Chi-squared, Fisher's exact test and Mann-Whitney's U. Twenty-eight point six percent of the adenomas had positive expression for hTERT. The variables significantly correlated with hTERT's expression were younger age of presentation, diagnostic of adenoma producer, higher PCNA index, higher CD34 density, increased GH on serum and the expression on PRL tissue, GH and ACTH. Tobacco history had a negative association with hTERT's expression. The telomerase could be a marker of cellular proliferation associated with angiogenesis and hormonal activity. Evaluation of these variables could provide information about their biological behavior.
Ortiz-Plata
Alma
A
Departamento de Neuropatología, Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez", Av. Insurgentes Sur 3877 Col La Fama, 14269, Mexico, D.F., Mexico. aortizplata@yahoo.com.mx
Tena Suck
Martha Lilia
ML
López-Gómez
Mario
M
Heras
Alfonso
A
Sánchez García
Aurora
A
D000236:Adenoma / Q000378:metabolism* / Q000473:pathology; D000328:Adult; D017668:Age of Onset; D018952:Antigens, CD34 / Q000096:biosynthesis*; D014408:Biomarkers, Tumor / Q000032:analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000378:metabolism* / Q000473:pathology; D018809:Proliferating Cell Nuclear Antigen / Q000096:biosynthesis*; D019098:Telomerase / Q000096:biosynthesis*
D018952:Antigens, CD34; D014408:Biomarkers, Tumor; D018809:Proliferating Cell Nuclear Antigen; C509186:TERT protein, human; D019098:Telomerase